Equity
-€30,477
Debts exceed assets in financial year 2025.
GYNTECH
Lifetime
20 annual accounts with figures on one time axis, 40 filings since 1986peak €91,441 (2009)
€5,554▼ 33.1%
lowest -€26,392 (2008)
€3,339▼ 41.5%
peak -€30,477 (2025)
-€30,477▲ €3,339
€50,835▼ 20.3%
peak 1 FTE (2006)
-not published
Board3 names since 1986
2 directors and 1 other
Documentsfilings and deeds
10-07-202621 days before the deadline
2025micro format
Gross margin from €8,300 to €5,554Result from €5,707 to €3,339Debts from €63,760 to €50,835Cash from €25,558 to €16,521
Key points
from the 2025 annual accountsDebts
€50,835 250% of the balance sheet
Suppliers 1%Taxes and wages 5%Other 93%
Position in the sector
-149.7%
Lower solvency than 92% of companies in wholesale trade. Sector median 40.5% · 15,447 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 3,795 companies had the same profile as GYNTECH has now. Each dot stands for 10 companies, two years later.
91.4%
were still trading
5.4%
stopped another way
2.7%
went bankrupt
Another 0.6% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,795 companies, not a prediction for GYNTECH. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0429381089
Resignation: (director)
Permanent representative: · Director discharge: · General meeting of 15-10-2025 · Gazette deed
Registered office moved from Schoten to Antwerp
New registered office: Delftstraat 29, 2140 Antwerpen · Previous registered office: Frans Reinemundlei 14, 2900 Schoten · Permanent representatives: and · Board meeting of 30-01-2024 · Gazette deed
Changes of role: (director) and (director)
“1) Groothandel in farmaceutische producten; 2) Systematische studies en creatieve inspanningen in diverse…” (deed in Dutch) · General meeting of 27-12-2023 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| GYNTECH Antwerp | €20,358 | €5,554 | -149.7% | - |
| CAPRICORN COMMUNICATION Ixelles | €27,186 | €7,672 | -547.9% | - |
| KINERGY Assenede | €30,483 | €8,054 | 38.5% | - |
| MEDIDAT Antwerp | €57,897 | €5,485 | 75.0% | - |
| Prothéses d'Oreille Utilitaires dans la Recherche et la Technologie Manage | €17,598 | €1,418 | -787.8% | - |
| Laboratoire du Docteur Vétérinaire Domicent Mons | €37,195 | €2,265 | 99.9% | - |
| REYNAERT RESEARCH Ghent | €46,825 | €13,058 | -71.1% | - |
These companies have the same main activity as GYNTECH: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €17,600 and €57,900, founded between 1968 and 1999.
Official details
Source: KBO- Status
- Active since 18-08-1986Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Establishment unit
- 2.035.246.4762140 Antwerp, since 25-09-1986
- Financial year end
- 31 December
- Peppol
- Reachable since 21-10-2026
Annual accounts 2025
- ≈ €65,000estimated
- €20,358▼ 32.0%
- Filing
- Filed on 10-07-2026, 21 days before the end of the filing period
Insights on GYNTECH
GYNTECH files the micro format. That format states no turnover. The gross margin fell from €72,452 in 2006 to €5,554 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about GYNTECH
- What is the company number of GYNTECH?
- The company number of GYNTECH is 0429.381.089. The VAT number is the same number with BE in front: BE 0429.381.089.
- Where is GYNTECH based?
- The registered office is at Delftstraat 29, 2140 Antwerp.Company details
- What does GYNTECH do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of GYNTECH?
- GYNTECH is a private limited company (BV).
- When was GYNTECH founded?
- GYNTECH was founded on 18-08-1986.
- Is GYNTECH still active?
- Yes, GYNTECH is an active enterprise in the KBO register.
- What is the turnover of GYNTECH?
- The turnover in financial year 2025 is ≈ €65,000. This figure is estimated from the gross margin of €5,554 and 53 comparable companies (NACE 464). It probably lies between €33,000 and €180,000. It is a rough estimate.Financials
- Is GYNTECH profitable?
- In financial year 2025, GYNTECH made a profit of €3,339.
- Where can I find the annual accounts of GYNTECH?
- GYNTECH filed 40 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of GYNTECH due?
- GYNTECH must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.